Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 494.58M P/E - EPS this Y -36.40% Ern Qtrly Grth -
Income -89.98M Forward P/E -7.84 EPS next Y -7.10% 50D Avg Chg 2.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 42.00%
Dividend N/A Price/Book 4.26 EPS next 5Y - 52W High Chg -14.00%
Recommedations 1.50 Quick Ratio 11.35 Shares Outstanding 48.85M 52W Low Chg 2,012.00%
Insider Own 3.10% ROA -31.13% Shares Float 41.31M Beta 2.40
Inst Own 107.69% ROE -48.16% Shares Shorted/Prior 6.39M/6.28M Price 12.46
Gross Margin - Profit Margin - Avg. Volume 502,761 Target Price 24.33
Oper. Margin - Earnings Date Nov 7 Volume 164,256 Change -1.35%
About Cabaletta Bio, Inc.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cabaletta Bio, Inc. News
11/18/24 Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
11/14/24 Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
11/06/24 Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
10/30/24 We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate
10/17/24 State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings
09/25/24 Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
08/28/24 Cabaletta Bio to Participate in Upcoming Investor Conferences in September
03:32 AM Several Headwinds Dragged Cabaletta Bio (CABA) in Q2
08/08/24 Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
07/08/24 Cabaletta Bio, Inc. (CABA): Why Are Analysts Loving This Shorted Stock Right Now?
07/02/24 Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
06/14/24 Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
05/29/24 Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
05/22/24 We Think Cabaletta Bio (NASDAQ:CABA) Can Afford To Drive Business Growth
05/15/24 Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
05/13/24 Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
03/23/24 Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway
06:00 AM Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
03/20/24 Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
03/08/24 Jim Cramer’s 10 Latest Stock Picks This Week
CABA Chatroom

User Image jerzypawlik Posted - 14 hours ago

$CABA Company with no debt, over 200 million in the bank, pt over $20 ,and tremendous pipeline training little over $2. Nice job MM'S.

User Image Magic8BallResponse Posted - 14 hours ago

@ThomasTrainTrader To be honest I like the $CABA program better but cash is king....

User Image jerzypawlik Posted - 14 hours ago

$CABA Scary tactics don't work on me. Loading as much I can.

User Image MiroslavBroz Posted - 15 hours ago

$CABA Who is buying these stocks that are selling off?

User Image Magic8BallResponse Posted - 15 hours ago

$CABA Bio trap. Market becomes uncertain about the ability to raise and the market cap implies massive dilution to complete the programs. Find a partner which will restore stock price which then can be used as leverage.... jmho

User Image ThomasTrainTrader Posted - 16 hours ago

@RamenLives Sorry to hear that man, I'm also down on my bio plays. $CABA unfortunately was poorly positioned nothing the company did specifically

User Image RamenLives Posted - 16 hours ago

$CABA I'm out... took a 12k fu(ken loss and am done with any new bio investments... going to pray NVDA dips hard after earning again and dump my remaining capital there.

User Image Enlaplaya2019 Posted - 16 hours ago

$CABA Going to ZERO!

User Image ThomasTrainTrader Posted - 17 hours ago

$KYTX Let's gooooooo another HC Wainwright downgrade who could've guessed. Keep in mind the reasoning is "potentially dilutive shares outstanding" when Kyverna has $321 million in cash and additional support from $GILD. Also keep in mind this guy has a $25 rating on $CABA when it has far less data and also 1/3 of the funding of Kyverna meaning it will definitely have to raise and dillute https://www.tipranks.com/news/the-fly/kyverna-therapeutics-price-target-lowered-to-6-from-7-at-h-c-wainwright

User Image Magic8BallResponse Posted - 17 hours ago

$CABA Kyverna reported $321.6 million in cash, cash equivalents, and available-for-sale marketable securities as of September 30, 2024

User Image Magic8BallResponse Posted - 17 hours ago

$CABA Let polish up those resumes folks!

User Image Magic8BallResponse Posted - 17 hours ago

$CABA How much funding is needed to complete pivotal trial? How many patients would need to be dosed?

User Image ThomasTrainTrader Posted - 17 hours ago

@Magic8BallResponse they base it off of usually high speculation on if a product succeeds or at least looks like it will pass phase 3. In a world where $CABA or any other company like $BMY gets a CAR-T autoimmune drug to market that asset is worth easily $1-3 billion. That’s where the $25+ price target came from. But CABA won’t get to market until earliest mid 2027, way after their funding runs out

User Image ThomasTrainTrader Posted - 17 hours ago

@Magic8BallResponse over enthusiasm and speculation in this space and also much less competition. $CABA quite literally doesn’t have the resources to compete with other CAR-T like $KYYX and $RNAC which were also overvalued earlier in the year.

User Image Magic8BallResponse Posted - 17 hours ago

$CABA What news caused the stock price to hit $25 earlier this year? What happened?

User Image Magic8BallResponse Posted - 17 hours ago

$CABA How do these analysts come up with these price targets? Do they just assume the company will raise at higher stock price????

User Image Magic8BallResponse Posted - 18 hours ago

$CABA Has the company outlined where the next tranche of funding is coming from? Do they have any development partnerships with big pharma?

User Image Magic8BallResponse Posted - 18 hours ago

$CABA Start slashing costs and the market will reward here.... jmho

User Image Magic8BallResponse Posted - 18 hours ago

$CABA Beginning to look like $ADAP $ACHL $BLUE ..... Runway is important and 2026 is closing in

User Image Magic8BallResponse Posted - 19 hours ago

$CABA What/when is the next catalyst?

User Image buddyopalosam Posted - 19 hours ago

$CABA Buying Sub 1. Waiting patiently

User Image Magic8BallResponse Posted - 20 hours ago

$CABA How much funding do they need to get a product to market and what is that in relation to market cap?

User Image MaeEscobar Posted - 20 hours ago

$FNA $CABA LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image dmeph Posted - 1 day ago

$CABA when's this week conference ? Any news from it ?

User Image RamenLives Posted - 1 day ago

$CABA Hopefully the bloodbath is over and the tutes start to buy up in mass at the huge discount.

User Image Magic8BallResponse Posted - 1 day ago

$CABA Bloated maybe?

User Image The1Ski Posted - 1 day ago

$CABA Reversal?

User Image _www_larval_com_ Posted - 1 day ago

$CABA 4%[-6%] $EOSE -3%[6%] $KSCP 3%[15%] $BTCT 3%[25%] most notable movement into the final minutes of trading.

User Image Magic8BallResponse Posted - 1 day ago

$CABA Management needs to address runway

User Image RamenLives Posted - 1 day ago

$CABA $4.78.... What is your average?

Analyst Ratings
HC Wainwright & Co. Buy Sep 17, 24
Wells Fargo Overweight Aug 12, 24
Evercore ISI Group Outperform Aug 12, 24
HC Wainwright & Co. Buy Aug 9, 24
Cantor Fitzgerald Overweight Jun 21, 24
Stifel Buy Jun 17, 24
HC Wainwright & Co. Buy Jun 14, 24
HC Wainwright & Co. Buy May 24, 24
HC Wainwright & Co. Buy May 16, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Binder Gwendolyn See Remarks See Remarks Jan 19 Sell 19.93 11,000 219,230 20,000 01/19/24
Binder Gwendolyn See Remarks See Remarks Jan 19 Option 1.01 11,000 11,110 31,000 01/19/24
Binder Gwendolyn See Remarks See Remarks Dec 19 Sell 21.99 11,000 241,890 20,000 12/19/23
Binder Gwendolyn See Remarks See Remarks Dec 19 Option 1.01 11,000 11,110 31,000 12/19/23
Binder Gwendolyn See Remarks See Remarks Oct 19 Sell 13.8 11,000 151,800 20,000 10/19/23
Binder Gwendolyn See Remarks See Remarks Oct 19 Option 1.01 11,000 11,110 31,000 10/19/23
Binder Gwendolyn See Remarks See Remarks Jul 19 Sell 13.96 11,000 153,560 20,000 07/19/23
Binder Gwendolyn See Remarks See Remarks Jul 19 Option 1.01 11,000 11,110 31,000 07/19/23
Binder Gwendolyn See Remarks See Remarks May 19 Sell 11.81 22,000 259,820 20,000 05/19/23
Binder Gwendolyn See Remarks See Remarks May 19 Option 1.01 22,000 22,220 42,000 05/19/23
Nichtberger Steven President & CEO President & CEO Oct 19 Buy 1.2492 8,127 10,152 986,483 10/19/22
Bollard Catherine Director Director Oct 18 Buy 0.9935 1,000 994 1,000 10/18/22
Marda Anup Chief Financial Offi.. Chief Financial Officer Oct 18 Buy 0.9924 50,000 49,620 50,000 10/18/22
Simon Mark Director Director Oct 18 Buy 0.98 125,000 122,500 7,000 10/18/22
Binder Gwendolyn See Remarks See Remarks Oct 18 Buy 0.9947 20,000 19,894 20,000 10/18/22
Nichtberger Steven President & CEO President & CEO Oct 18 Buy 0.9939 141,873 141,008 978,356 10/18/22